Estimated wasteful spending on aducanumab dispensing in the U.S. Medicare population: A cross-sectional analysis.

TitleEstimated wasteful spending on aducanumab dispensing in the U.S. Medicare population: A cross-sectional analysis.
Publication TypeJournal Article
Year of Publication2022
AuthorsOronce, CIrwin A, Arbanas, JCave, Leng, M, Landon, BE, Damberg, CL, Sarkisian, C, Mafi, JN
JournalJournal of the American Geriatrics Society
Volume70
Issue9
Pagination2714-2718
ISSN Number1532-5415
KeywordsAlzheimer disease, drugs, Medicare, Spending
Abstract

Aducanumab, a weight-dosed Alzheimer's drug with uncertain benefits and high cost, could strain Medicare's budget if approved for widespread use.1 In April 2022, Medicare issued a final determination restricting aducanumab's use to clinical trials. However, Medicare's coverage decision may still be overturned by legal challenges, potentially leading to much higher uptake.2 Moreover, several other Alzheimer's infusion drugs similar to aducanumab are currently in the development pipeline.3

Because aducanumab is available in two fixed-dose vial sizes, its use may result in large amounts of discarded drug and wasteful spending.4, 5 To quantify the amount of discarded drug and potential savings that could be generated from more efficient aducanumab vial sizes, we analyzed patient weight distributions from a nationally representative sample of Medicare beneficiaries with mild cognitive impairment (MCI) or mild dementia.

DOI10.1111/jgs.17891
Citation Key12504
PubMed ID35758317
PubMed Central IDPMC9489619
Grant ListR01AG070017-01 / AG / NIA NIH HHS / United States
R01AG058878-03 / AG / NIA NIH HHS / United States
1K24AG047899-01 / AG / NIA NIH HHS / United States
K76AG064392-01A1 / AG / NIA NIH HHS / United States
2R24AG064025 / / U.S. Deprescribing Research Network /
L1TR001881 / / UCLA CTSI NIH/National Center for Advanced Translational Science Grant /
R01HS026498-04 / / Agency for Healthcare Research and Quality /
/ / VA Advanced Health Services Research Fellowship /